David I. Stirling

Dr. Stirling is Chair of the Board of NovoMedix. He also serves as a Director of BioTheryX, Inc., a clinical-stage Targeted Protein Degrader company that he Co-founded. He was a Co-Founder of Celgene, and was its former Chief Scientific Officer and Executive Vice President, Pharmaceutical Research & development. He was responsible for initiating the Thalidomide Clinical and Research Program, which led to Celgene’s first clinical product. Under Dr. Stirling’s leadership, the blockbuster franchise of Thalomid derivatives (Revlimid®, Pomalyst®, Otezla®) were developed, and these played a major role in propelling Celgene into the top-tier of public biotechnology companies worldwide resulting in its acquisition by Bristol Myer Squibbs. Dr. Stirling received his Ph.D. in Biochemistry from the University of Warwick in England, where he studied the industrial applications of novel oxygenase enzymes. Dr. Stirling is the author of numerous publications, and holds over 30 U.S. patents.